FDA approves Mylan's biosimilar for breast, stomach cancer: 4 things to know

The FDA approved Mylan's biosimilar cancer drug Ogivri Dec. 1.

Here are four things to know.

1. Ogivri is a biosimilar version of Genentech's cancer drug Herceptin.

2. The drug is intended to treat patients with breast or metastatic stomach cancer.

3. Ogivri is the second biosimilar approved for cancer, and the first approved to treat stomach and breast cancer.

4. Both Ogivri and Herceptin contain a boxed warning over an increased risk of heart disease, infusion reactions, lung damage and harm to fetuses.

More articles on supply chain:
Pfizer to launch generic version of Viagra at $33 per pill
FDA urges drugmaker to recall osteoarthritis product following liver and lung injury reports
Amazon withdraws application for pharmacy license in Maine

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months